Yes, Zepbound Is Approved for Weight Loss
Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition like hypertension, dyslipidemia, or type 2 diabetes. It's administered as a weekly injection, starting at 2.5 mg and increasing to a maximum of 15 mg based on tolerance and response.[1]
How Zepbound Works for Weight Loss
Tirzepatide mimics two gut hormones—GLP-1 and GIP—to reduce appetite, slow gastric emptying, and improve insulin sensitivity. In clinical trials like SURMOUNT-1, patients lost an average of 15-21% of body weight over 72 weeks, far exceeding placebo (about 3%).[1][2]
Zepbound vs. Mounjaro: Same Drug, Different Labels
Zepbound is the weight-loss branded version of tirzepatide from Eli Lilly. Mounjaro uses the same active ingredient but is approved only for type 2 diabetes. Dosing and pens are identical, but insurance coverage often differs—Zepbound faces more restrictions for weight loss.[1]
Who Qualifies and How to Get It
Eligible patients need a BMI meeting criteria plus medical supervision. It's not for cosmetic use or those with medullary thyroid carcinoma history. Prescriptions come from doctors or telehealth; list price is $1,060/month, but savings cards cut it to $25 for eligible insured patients.[1][3]
Common Side Effects Patients Report
Nausea (up to 30% in trials), diarrhea, vomiting, and constipation are most frequent, usually mild and fading over time. Rare risks include gallbladder issues, pancreatitis, or thyroid tumors (from animal studies). Monitor for low blood sugar if on other diabetes meds.[1][2]
When Does Zepbound's Patent Expire?
Eli Lilly holds patents on tirzepatide until at least 2035-2036 for composition and use in weight loss, per DrugPatentWatch. Challenges from competitors like Viking Therapeutics could shorten exclusivity, but no generics are imminent.[4]
Cost, Coverage, and Alternatives
Without insurance, it's pricey at ~$1,000/month. Medicare excludes weight-loss drugs, but some private plans cover it post-prior authorization. Alternatives include Wegovy (semaglutide, ~15% weight loss) or older options like phentermine. Compounded tirzepatide is cheaper (~$300/month) but unregulated and risky.[1][3]
Sources
[1]: FDA Label for Zepbound
[2]: NEJM SURMOUNT-1 Trial
[3]: Eli Lilly Zepbound Site
[4]: DrugPatentWatch: Tirzepatide Patents